Ocugen wins provisional approval for OCU400 in Bahamas under LARTA pathway
Bitget2026/09/25 11:02- Ocugen won provisional approval, priority designation in The Bahamas for OCU400 modifier gene therapy in retinitis pigmentosa.
- Regulator LARTA Board put the program on an expedited pathway toward full approval.
- Company plans expanded access supply, targeting first patient dosing within 90 days of full approval.
- OCU400 remains in Phase 3, with topline data expected in 1Q 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Bank of Japan minutes turn hawkish: Most members believe a rate hike is needed soon, with a 70% probability of a hike in December
Minutes from the Bank of Japan show that several members believe a rate hike is needed in the near term, with a roughly 70% probability of an increase in December. Core inflation has met the target for the first time in 30 years, and the current policy rate stands at 1.25%.
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
Crypto prices
More
